---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013486"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:08:16.756620+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aprea reports preliminary Phase 1 safety data for WEE1 inhibitor APR-1051; no hematologic toxicity

## Summary
- APR-1051 safe and well-tolerated in first three patients; all adverse events Grade 1-2, no neutropenia or QT prolongation.
- Phase 1 ACESOT-1051 study evaluating 10–150 mg daily doses; 8 cohorts planned, subtherapeutic doses given in cohorts 1-3.
- Data cutoff Oct 7, 2024: one patient progressed at 49 days, one withdrew at 36 days, third continues on treatment.
- Active enrollment at 3 U.S. sites (NEXT Oncology in San Antonio & Dallas, MD Anderson); preliminary efficacy data expected in 2025.
- APR-1051 designed for selective WEE1 inhibition without PLK off-target effects seen with other WEE1 inhibitors.

## SEC filing metadata
- accession: 0001558370-24-013486
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837024013486/0001558370-24-013486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837024013486/apre-20241023x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013486
- JSON: https://secwatch.observer/filing/0001558370-24-013486.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.